Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina

Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina: A Randomised, Double-blind, Placebo-controlled Clinical Trial

Compared with placebo, assess of the efficacy and safety of Guanxin Shutong capsule to treat chronic stable angina (syndrome of blood stasis resistance), and the result will be used for the basis of later Ⅳ clinical trial.

Study Overview

• Status: Unknown
• Conditions: Angina, Stable
• Intervention / Treatment: Drug: Guanxin Shutong Capsule; Drug: nitroglycerine; Drug: Placebo Capsule

Detailed Description

1. Procedures 1.1 Start-up stage (-14~0 Day)

1. Inquire medical history, medication use, accompanied treatment, etc;
2. Sign informed consent;
3. Measure vital signs and conduct physical examination;
4. Record symptom and signs;
5. Confirm inclusion/exclusion criteria, and put patients who meet inclusion criteria into start-up stage;
6. Record participators' history of angina pectoris and treatment, or select stable angina from outpatient service (without medicate);
7. Allocate screen number, hand out Guanxi Shutong Capsules Placebo and record card of angina/nitroglycerin used;
8. Advise patient return visit with an empty belly 2 weeks later. 1.2 Interview 1 (Baseline 0 Day)

(1) Measure vital signs; (2)Accomplish all the examination items: Blood routines, Urine routines, Stool routines + Occult blood, Hepatorenal function (AST, ALT, TBIL, ALP, γ-GT, BUN, Cr), Four coagulation tests (TT, PT, APTT, FIB), Blood fat (TC, TG, HDL-C, LDL-C), 12 leads electrocardiogram, Seattle Angina Ques-tionnaire (SAQ). Additionally, premenopausal women receive urine pregnancy test; (3) Exercise treadmill testing (ETT): around am. 10:00 (Note: Just for the patients who need ETT); (4) Record symptoms and signs ( Score of syndrome of Chinese medicine and Score of angina); (5) Randomize and allocate drug number; (6) Hand out the drugs for 2 weeks and record card of angina/nitroglycerin used; (7) Advise patient return visit 2 weeks later. 1.3 Interview 2 (14±2 Day)

1. Inquire adverse events;
2. Inquire accompanied treatment and record combined medication.
3. Measure vital signs;
4. Record symptoms and signs (Score of syndrome of Chinese medicine and Score of angina);
5. Withdraw remained drugs and box, and record card;
6. Hand out the drugs for 2 weeks and record card of angina/nitroglycerin used;
7. Advise patient return visit 2 weeks later. 1.4 Interview 3 (28±2 Day)

(1) Inquire adverse events; (2) Inquire accompanied treatment and record combined medication. (3) Measure vital signs; (4) Record symptoms and signs (Score of syndrome of Chinese medicine and Score of angina); (5) 12 leads electrocardiogram (6) Accomplish all the examination items: Blood routines, Urine routines, Stool routines + Occult blood, Hepatorenal function (AST, ALT, TBIL, ALP, γ-GT, BUN, Cr), Four coagulation tests (TT, PT, APTT, FIB), Blood fat (TC, TG, HDL-C, LDL-C), 12 leads electrocardiogram, Seattle Angina Ques-tionnaire (SAQ); (7) Exercise treadmill testing (ETT) (Note: Just for the patients who need ETT); (8) Withdraw remained drugs and box, and record card; (9) Assess compliance; (10) Summarize the clinical trial.

• Study Type: Interventional
• Enrollment (Anticipated): 300
• Phase: Phase 4

Contacts and Locations

• Study Contact: Name: Han Yaling, Academician; Phone Number: +86-24-28856123; Email: guanxinshutong@126.com

Study Locations

• China
  • Liaoning
    • Shenyang, Liaoning, China, 110045
      • The General Hospital Of Shenyang Military Region
      • Contact: Han Yaling, Academician; Phone Number: +86-24-28856123; Email: guanxinshutong@126.com

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Symptom of chronic stable angina is sustained for 3 months or over 3 months (typical symptoms of myocardial ischemia occurred at least 2 times in the latest week, and angina type is stable angina (Canada CCS class Ⅰ、Ⅱ or Ⅲ);
• Blood stasis resistance on traditional Chinese medicine syndrome differentiation;

• Patients who meet the following any situation:

  1. had coronary angiography and verified a least one main branch of coronary stenosis ≥50%;
  2. have typical angina symptom, and also have positive ETT result or CTA shows at least one main branch of coronary stenosis ≥50%;
  3. had history of myocardial infarct (at least 6 months).
• Written informed consent.

Exclusion Criteria:

• Acute coronary syndrome or highly suspected acute coronary syndrome;
• Variant angina or unstable angina;
• Myocardial infarction within the past 6 months;
• Left main disease and without revascularization was verified through angiography or CTA;
• Moderate to severe aortic stenosis, hypertrophic Obstructive Cardiomyopathy or congestive heart-failure (NYHA class Ⅲ-Ⅳ);
• Patients who were received PCI/CABG within 1 year;
• Patients who are poor control of high blood pressure (SBP>170mmHg, or DBP>100mmHg);
• Patients who have hypotension (SBP<90mmHg, DBP<60mmHg) or had orthostatic hypotension;
• ECG shows complete left bundle branch block, pre-excitation syndrome, left ventricular hypertrophy or pacemaker rhythm;
• Hypohepatia (ALT or bilirubin level is higher than upper limit), renal insufficiency (serum creatinine level is higher than upper limit);
• Active peptic ulcer or skin ulcer;
• Diagnosed chest pain caused by severe neurosis, menopausal syndrome, hyperthyroidism, cervical spondylosis, gallbladder-cardiac syndrome, gastroesophageal reflux, esophageal hiatus hernia or in aortic dissection;
• Patients had hematological disorder, specific bleeding or warfarin caused bleeding;
• Drug abuser, patients with history of alcoholism in the past 2 years or dependency to known drugs;
• Psychopath;
• Patients who can't compelet exercise test (note: just for partial patients who need to complete exercise test);
• Pregnancy or lactation;
• Patients who are known or suspected hypersensitive to the study medicine or allergic constitution;
• Patients who were received big surgery within 4 weeks or participated in other clinical trials within 3 months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Guanxin Shutong Capsule; 3 capsules once, tid, Oral Duration: 4 weeks	Drug: Guanxin Shutong Capsule; 3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.; Drug: nitroglycerine; Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently. The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts.
Placebo Comparator: Placebo Capsule; Placebo capsule and Guanxin Shutong Capsule the same appearance are made by SHAANXI BUCHANG PHARMACEUTICAL CO.,LTD. 3 capsules once, tid, Oral Duration: 4 weeks	Drug: nitroglycerine; Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently. The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts.; Drug: Placebo Capsule; 3 capsules three times a day; Duration: 4 weeks.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Therapeutic effect to Angina ( Average value of angina frequency)	Record angina frequency per week. Record date is Start-up Stage 1st week, Start-up Stage 2st week, Interview Stage 1st week, Interview Stage 2st week, Interview Stage 3st week and Interview Stage 4st week (Toal of 6 times).	6 weeks
Exercise treadmill testing (ETT)	ST-segment displacement in electrocardiogram: Observe ST-segment displacement of J point after 60ms, including the degree of ST-segment depression.	4 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Usage of nitroglycerine per day (average value)		4 weeks
Seattle Angina Ques-tionnaire (SAQ)		4 weeks
Scores on Chinese medical syndrome scale	Primary symptom: Chest pains (0; Slight: 2; Moderate: 4; Severe: 6) Chest congestion (0; Slight: 2; Moderate: 4; Severe: 6) Secondary symptom: Palpitation (0; Slight: 1; Moderate: 2; Severe: 3) Shortness of breath (0; Slight: 1; Moderate: 2; Severe: 3) Insomnia (0; Slight: 1; Moderate: 2; Severe: 3)	4 weeks
Electrocardiogram manifestation	Compare the changes of electrocardiogram manifestation (such as ST segment, T wave) of angina before and after treatment.	4 weeks
Time of angina break out from exercise beginning in ETT		4 weeks
Time of ST below 1 mm from exercise beginning in ETT		4 weeks

Other Outcome Measures

Outcome Measure	Time Frame
Blood fat (TC, TG, HDL-C, LDL-C)	4 weeks
Degree and duration of angina attack.	4 weeks

Collaborators and Investigators

• Sponsor: Shaanxi Buchang Pharmaceutical Co., Ltd
• Investigators: Principal Investigator: Lv Shuzheng, Beijing Anzhen Hospital; Principal Investigator: Zhang Yan, The Affiliated Hospital of Liaoning Hospital of Traditional Chinese Medicine; Principal Investigator: Chen Bojun, The Second Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine; Principal Investigator: Luo Wei, XuZhou Central Hospital; Principal Investigator: Jiang Binghua, The Second Affiliated Hospital of Shandong University of traditional Chinese Medicine; Principal Investigator: Zhang Zhenxian, Luohe Hospital of traditional Chinese Medicine; Principal Investigator: Xing Yanjun, First Hospital of Shijiazhuang City

Publications and helpful links

General Publications

• Li Y, Zhang L, Lv S, Wang X, Zhang J, Tian X, Zhang Y, Chen B, Liu D, Yang J, Dong P, Xu Y, Song Y, Shi J, Li L, Wang X, Han Y. Efficacy and safety of oral Guanxinshutong capsules in patients with stable angina pectoris in China: a prospective, multicenter, double-blind, placebo-controlled, randomized clinical trial. BMC Complement Altern Med. 2019 Dec 11;19(1):363. doi: 10.1186/s12906-019-2778-z.

Study record dates

Study Major Dates

• Study Start: October 1, 2014
• Primary Completion (Anticipated): June 1, 2015
• Study Completion (Anticipated): October 1, 2015

Study Registration Dates

• First Submitted: October 23, 2014
• First Submitted That Met QC Criteria: October 29, 2014
• First Posted (Estimate): November 2, 2014

Study Record Updates

• Last Update Posted (Estimate): November 2, 2014
• Last Update Submitted That Met QC Criteria: October 29, 2014
• Last Verified: October 1, 2014

More Information

Terms related to this study

• Keywords: Angina
• Additional Relevant MeSH Terms: Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Pain; Neurologic Manifestations; Chest Pain; Angina Pectoris; Angina, Stable; Vasodilator Agents; Nitroglycerin
• Other Study ID Numbers: YL-CTP-Z20020055